Abstract
Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score ≤45]; treated with olanzapine for 1-24 months; and who had gained ≥5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean±S.D.: -0.19±4.58 versus 1.28±4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 13-21 |
| Number of pages | 9 |
| Journal | European Neuropsychopharmacology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2005 |
Fingerprint
Keywords
- Amantadine
- Bipolar I disorder
- Olanzapine
- Schizophrenia
- Weight gain
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Biological Psychiatry
- Neurology
- Pharmacology
- Psychology(all)
Cite this
Amantadine for weight gain associated with olanzapine treatment. / Deberdt, Walter; Winokur, Andrew; Cavazzoni, Patrizia A.; Trzaskoma, Quynh N.; Carlson, Christopher D.; Bymaster, Frank P.; Wiener, Karen; Floris, Michel; Breier, Alan.
In: European Neuropsychopharmacology, Vol. 15, No. 1, 01.2005, p. 13-21.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Amantadine for weight gain associated with olanzapine treatment
AU - Deberdt, Walter
AU - Winokur, Andrew
AU - Cavazzoni, Patrizia A.
AU - Trzaskoma, Quynh N.
AU - Carlson, Christopher D.
AU - Bymaster, Frank P.
AU - Wiener, Karen
AU - Floris, Michel
AU - Breier, Alan
PY - 2005/1
Y1 - 2005/1
N2 - Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score ≤45]; treated with olanzapine for 1-24 months; and who had gained ≥5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean±S.D.: -0.19±4.58 versus 1.28±4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.
AB - Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score ≤45]; treated with olanzapine for 1-24 months; and who had gained ≥5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean±S.D.: -0.19±4.58 versus 1.28±4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.
KW - Amantadine
KW - Bipolar I disorder
KW - Olanzapine
KW - Schizophrenia
KW - Weight gain
UR - http://www.scopus.com/inward/record.url?scp=9644308090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9644308090&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2004.03.005
DO - 10.1016/j.euroneuro.2004.03.005
M3 - Article
C2 - 15572269
AN - SCOPUS:9644308090
VL - 15
SP - 13
EP - 21
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
SN - 0924-977X
IS - 1
ER -